Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast

[News]

Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.

More... (http://www.news-medical.net/news/20121103/Adding-angiogenesis-inhibitor-to-anti-HER2-drugs-extends-survival-in-mice-with-breast-cancer.aspx)